Zinc Finger Protein
Zinc Finger Protein
Zinc Finger Proteins (ZFPs) comprise the largest family of transcription factors, characterized by finger-like DNA-binding domains. The zinc-finger domain is one of the most common DNA-binding motifs found in eukaryotic transcriptional regulators. The most prevalent types of zinc-finger domain proteins include C2H2 (e.g., ZNF217), RING (e.g., E3-ubiquitin ligase), PHD (e.g., KDM2A), and LIM (e.g., Lin-11, Isl-1, and Mec-3) types. ZFPs are capable of interacting with DNA, RNA, poly-ADP-ribose (PAR), and other proteins, thereby facilitating diverse roles in cellular functions such as cell differentiation, apoptosis, transcriptional regulation, metabolism, and immune responses.
ZFPs, including ZNF281, ZNF750, ZNF185, and ZBP89, are implicated in tumorigenesis, cancer progression, and metastasis formation, highlighting their significance in oncogenic processes[1].
ZFPs, including ZNF281, ZNF750, ZNF185, and ZBP89, are implicated in tumorigenesis, cancer progression, and metastasis formation, highlighting their significance in oncogenic processes[1].
All Product Categories
-
Zinc Finger Protein Produits associés (10)
Produits associés (10)
-
Zomiradomide
0 ImagesSynonyms: KT-413Zomiradomide (KT-413) is an orally active IRAK4 PROTAC degrader with a DC50 of 6 nM. Zomiradomide inhibits the NF-κB signaling pathway, while its molecular glue function mediates the degradation of Ikaros and Aiolos (with a DC50 of 1 nM for both), activates the IFN-I signaling pathway, and selectively degrades IMiD substrates. Zomiradomide inhibits cancer cell proliferation and tumor growth. Zomiradomide can be used in research related to B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma.
-
ZNF207-IN-1
0 ImagesZNF207-IN-1 is an orally active and brain-penetrant ZNF207 inhibitor with a target KD of 67 nM. ZNF207-IN-1 binds directly to ZNF207, downregulates stem-related genes and weakens glioma cell stemness. ZNF207-IN-1 hinders tumorigenesis and migration and promotes apoptosis. ZNF207-IN-1 can be used for the research of glioma[1].
-
Cisd2 agonist 2
0 ImagesCisd2 agonist 2 (compound 6) is a Cisd2 activator (EC50=191 nM), and Cisd2 levels are associated with non-alcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant in vivo toxicity in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout). Cisd2 (CDGSH iron sulfur domain 2) is a zinc finger protein that is mainly localized in the endoplasmic reticulum or mitochondrial membrane. Cisd2 participates in mitochondrial function by forming homodimers containing two redox-active 2Fe-2S clusters.
-
Schnurri-3 inhibitor-1
0 ImagesSchnurri-3 inhibitor-1 is a potent schnurri-3 inhibitor which is an essential regulator of adult bone formation. Schnurri-3 inhibitor-1 can inhibit Shn3 with EF1alpha promoter in osteoblast cell line Shn3FFL with an AC50 value of 2.09 μM. Schnurri-3 inhibitor-1 can be used to research osteoporosis.
-
ZNF281-IN-1
0 ImagesCat. No.: HY-183629ZNF281-IN-1 is a ZNF281 inhibitor. ZNF281-IN-1 disrupts the binding of transcriptionally active DNA-bound ZNF281 to the promoters of target genes including TRIM35 and ZEB1. ZNF281-IN-1 inhibits tumor cell proliferation, stabilizes P53 and upregulates PUMA to induce apoptosis, while triggering cellular senescence. ZNF281-IN-1 completely prevents Doxorubicin (HY-15142A)-induced cardiotoxicity (AIC), and enhances rather than impairs the antitumor efficacy of Doxorubicin. ZNF281-IN-1 completely blocks the distant metastasis of melanoma to the lungs. ZNF281-IN-1 can be used in the research of cardiotoxicity, lung cancer and metastatic melanoma.
-
HRZ-01-082-5
0 ImagesCat. No.: HY-175875CAS No.: 3090685-19-8HRZ-01-082-5 is an analog of Glutarimide (HY-I0466). HRZ-01-082-5 is a dual-functional molecular glue degrader of SALL4 and OSR1 with a DC50 4.8 nM for OSR1. HRZ-01-082-5 significantly induced SALL4 and OSR1 degradation through CRBN. HRZ-01-082-5 can be used for heart and urogenital development, as well as cancers research.
-
PLAGL2-IN-1
0 ImagesCat. No.: HY-180281CAS No.: 3099026-16-8PLAGL2-IN-1 is a inhibitor of pleiomorphic adenoma-like protein 2 (PLAGL2) with a Kd of 2.23 µM. PLAGL2-IN-1 suppresses PLAGL2 transcriptional activity, induces G0/G1 cell cycle arrest, and apoptosis, thereby inhibiting hepatocellular carcinoma (HCC) cell proliferation. PLAGL2-IN-1 disrupts extracellular matrix organization and suppresses the PI3K-AKT pathway by reducing AKT phosphorylation. PLAGL2-IN-1 inhibits tumor growth in an HCCLM3 xenograft mouse model. PLAGL2-IN-1 can be used for the research of HCC.
-
XD2-149
0 ImagesCat. No.: HY-159570CAS No.: 2710221-08-0XD2-149 is a ZFP91 PROTAC degrader with DC50 values of 0.08 μM and 0.06 μM, respectively. ZFP91 is a bifunctional nuclear protein with both transcription factor and E3 ubiquitin ligase activities, and is classified as an oncogenic non-canonical NF-κB pathway regulator in tumor and immune regulation. XD2-149 induces proteasome-dependent degradation of the E3 ubiquitin-protein ligase ZFP91. XD2-149 inhibits the STAT3 signaling pathway in pancreatic cancer cells and induces NQO1-dependent cell death independent of ZFP91 degradation. XD2-149 can be used for the research of pancreatic cancer.
-
YPC-22026
0 ImagesCat. No.: HY-120264CAS No.: 1964457-41-7YPC-22026 is a zinc-finger protein 143 (ZNF143) inhibitor with an IC50 value of 9.0 μM. YPC-22026 is a potent tumor regression inducer. YPC-22026 exhibits anti‐tumor activities.
